Intra-Cellular Therapies Inc (ITCI)
71.21
+0.20
(+0.28%)
USD |
NASDAQ |
May 07, 16:00
71.16
-0.05
(-0.07%)
After-Hours: 20:00
Intra-Cellular Therapies Cash from Investing (TTM): 105.54M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 105.54M |
September 30, 2023 | 108.38M |
June 30, 2023 | 234.72M |
March 31, 2023 | 177.20M |
December 31, 2022 | -128.37M |
September 30, 2022 | -127.13M |
June 30, 2022 | -169.52M |
March 31, 2022 | -157.96M |
December 31, 2021 | 280.34M |
September 30, 2021 | 52.50M |
June 30, 2021 | -154.49M |
March 31, 2021 | -211.04M |
December 31, 2020 | -480.30M |
September 30, 2020 | -266.22M |
June 30, 2020 | -82.77M |
March 31, 2020 | -20.29M |
December 31, 2019 | 177.44M |
September 30, 2019 | 153.85M |
June 30, 2019 | 141.87M |
Date | Value |
---|---|
March 31, 2019 | 116.11M |
December 31, 2018 | 134.64M |
September 30, 2018 | -31.39M |
June 30, 2018 | -22.49M |
March 31, 2018 | -20.57M |
December 31, 2017 | -92.72M |
September 30, 2017 | 60.84M |
June 30, 2017 | 76.65M |
March 31, 2017 | 73.82M |
December 31, 2016 | 92.26M |
September 30, 2016 | -160.35M |
June 30, 2016 | -258.91M |
March 31, 2016 | -285.51M |
December 31, 2015 | -361.78M |
September 30, 2015 | -112.29M |
June 30, 2015 | -84.54M |
March 31, 2015 | -133.44M |
December 31, 2014 | -66.73M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-480.30M
Minimum
Dec 2020
280.34M
Maximum
Dec 2021
-19.28M
Average
-20.29M
Median
Mar 2020
Cash from Investing (TTM) Benchmarks
Johnson & Johnson | -2.901B |
Insmed Inc | -223.60M |
Vertex Pharmaceuticals Inc | -3.142B |
Fate Therapeutics Inc | 112.66M |
ADMA Biologics Inc | -4.981M |